Please enable Javascript
Leah Sherwood
Articles by Leah Sherwood
European Commission Grants Marketing Authorization to Luspatercept
Leah Sherwood
Myelodysplastic Syndromes
|
March 24, 2023
The EC approval of luspatercept was based on results from the phase II BEYOND study.
Read More
FDA Approves Nelarabine Injection for T-ALL, T-LBL
Leah Sherwood
T-Cell Lymphoma
|
March 24, 2023
The approval of the treatment provides patients with an alternative to a product that has historically been in shortage.
Read More
Molly Stoddart, RN, BSN, on Clinical Research Nursing in Multiple Myeloma
Leah Sherwood
Myeloma
|
March 17, 2023
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Read More
FDA Accepts NDA of ADX-2191 for Priority Review
Leah Sherwood
Aggressive B-Cell Lymphoma
|
March 16, 2023
ADX-2191 is a sterile, noncompounded intravitreal formulation of methotrexate.
Read More
FDA ODAC Gives Green Light to First-Line Polatuzumab Vedotin-Piiq Plus R-CHP in DLBCL
Leah Sherwood
Aggressive B-Cell Lymphoma
|
March 10, 2023
The FDA is expected to make a final decision on the supplemental BLA for polatuzumab vedotin-piiq in DLBCL in early April.
Read More
MDS, AML Early Predictors of COVID-19 Treatment Failure
Leah Sherwood
Myelodysplastic Syndromes
|
March 6, 2023
MDS/AML are among independent predictors of COVID-19 treatment failure.
Read More
FDA Approves IND for EP0042
Leah Sherwood
Acute Myeloid Leukemia
|
March 1, 2023
The FDA has approved an Investigational New Drug application for EP0042, a dual FLT-3 and aurora kinase inhibitor.
Read More
OPTIMUM/MUKnine Trial Supports Extended, Risk-Stratified Post-AHSCT Therapy in Newly Diagnosed Ultrahigh-Risk Multiple Myeloma
Leah Sherwood
Myeloma
|
February 27, 2023
The OPTIMUM/MUKnine clinical trial aimed to reduce the risk of relapse before and after AHSCT in ultrahigh-risk MM.
Read More
FDA Grants Fast Track Status to AB-101/Rituximab Combination for Relapsed, Refractory B-Cell NHL
Leah Sherwood
Aggressive B-Cell Lymphoma
|
February 27, 2023
AB-101 is an allogeneic, cryopreserved, ADCC-enhancing natural killer-cell therapy.
Read More
FDA Grants Priority Review to Elranatamab for Relapsed/Refractory Multiple Myeloma
Leah Sherwood
Myeloma
|
February 23, 2023
The new FDA decision follows its granting of Breakthrough Therapy Designation to elranatamab in November 2022.
Read More
AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome
Leah Sherwood
|
February 21, 2023
The AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome took place from January 23-25, 2023.
Read More
California Cancer Care Equity Act Takes Aim at Disparities in Access to Cancer Care
Leah Sherwood
Acute Myeloid Leukemia
|
February 20, 2023
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
Read More
Study Ties Prevalence of Delirium to Worse Outcomes in Hospitalized Patients Undergoing HSCT
Leah Sherwood
Transplantation & Cellular Therapy
|
February 17, 2023
The study used natural language processing for computer-assisted review of electronic health records.
Read More
Study Validates Presence of Immunotherapeutic Targets for Multiple Myeloma
Leah Sherwood
Myeloma
|
February 15, 2023
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Read More
Ponatinib More Effective Than Imatinib in Newly Diagnosed Ph+ ALL
Leah Sherwood
Acute Lymphoblastic Leukemia
|
February 15, 2023
Ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy in newly diagnosed Ph+ ALL.
Read More
Rashmi Kanagal-Shamanna, MD, Discusses Optical Genome Mapping
Leah Sherwood
Acute Myeloid Leukemia
|
February 13, 2023
The optical genome mapping platform will have clinical implications for patients with acute myeloid leukemia and MDS.
View More
Acquired Mutations in BAX Confer Resistance to Venetoclax Treatment for AML
Leah Sherwood
Acute Myeloid Leukemia
|
February 13, 2023
These results have potential implications for the long-term success of venetoclax therapy.
Read More
EHA-EBMT 5th European CAR T-Cell Meeting
Leah Sherwood
|
February 10, 2023
The EHA-EBMT 5th European CAR T-Cell Meeting was held February 9-11 in Rotterdam, Netherlands.
Read More
Pembrolizumab Demonstrates Good Safety After CAR T-Cell Therapy in R/R DLBCL
Leah Sherwood
Aggressive B-Cell Lymphoma
|
February 10, 2023
The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response.
Read More
Study Finds Patients with MDS Plus DDX41 Mutations Progress Rapidly to AML
Leah Sherwood
Acute Myeloid Leukemia
|
February 8, 2023
The study also found DDX41 germline variants explained approximately 80% of known germline predisposition to MNs in adults.
Read More
Load More